Stifel Financial Corp lowered its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 3.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 910,031 shares of the biopharmaceutical company’s stock after selling 33,359 shares during the period. Stifel Financial Corp owned about 0.06% of Bristol-Myers Squibb worth $47,307,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Riverview Trust Co acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $33,000. Portfolio Solutions LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $37,000. Gantzert Investment Co. LLC ADV acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $39,000. 1 North Wealth Services LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $42,000. Finally, Berman Capital Advisors LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $63,000. Institutional investors and hedge funds own 74.28% of the company’s stock.
Shares of BMY traded down $0.28 during mid-day trading on Friday, hitting $45.52. 23,633,791 shares of the company’s stock were exchanged, compared to its average volume of 19,861,882. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.50 and a current ratio of 1.61. The company has a market capitalization of $74.38 billion, a price-to-earnings ratio of 11.44, a price-to-earnings-growth ratio of 2.34 and a beta of 0.79. Bristol-Myers Squibb Co has a fifty-two week low of $44.30 and a fifty-two week high of $63.69.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a $0.41 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $1.64 dividend on an annualized basis and a yield of 3.60%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.21%.
A number of research firms have commented on BMY. Zacks Investment Research cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Thursday, March 28th. BMO Capital Markets upped their price target on Bristol-Myers Squibb from $62.00 to $63.00 and gave the stock an “outperform” rating in a research note on Wednesday. ValuEngine cut Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Thursday, April 4th. Bank of America cut their price objective on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 19th. Finally, Edward Jones lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Friday, January 4th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $59.14.
COPYRIGHT VIOLATION WARNING: “Stifel Financial Corp Sells 33,359 Shares of Bristol-Myers Squibb Co (BMY)” was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.baseballdailydigest.com/news/2019/04/21/stifel-financial-corp-has-47-31-million-position-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Read More: Do You Need a Fiduciary?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.